While they stressed that more research was needed, the study gave hope that the cannabis, if proven to modulate the enzyme, “may prove a plausible strategy for decreasing disease susceptibility” as well as “become a useful and safe addition to the treatment of COVID-19 as an adjunct therapy.”
Cannabis could even be used to “develop easy-to-use preventative treatments in the form of mouthwash and throat gargle products,” the study suggested, with a “potential to decrease viral entry” through the mouth.
“The key thing is not that any cannabis you would pick up at the store will do the trick,” Olga told CTV, with the study suggesting just a handful of more than 800 varieties of sativa seemed to help.
All were high in anti-inflammatory CBD — but low in THC, the part that produces the cannabis high.
The study, which has yet to be peer-reviewed, was carried out in partnership with Pathway Rx, a cannabis therapy research company, and Swysh Inc., a cannabinoid-based research company.
The researchers are seeking funding to continue their efforts to support scientific initiatives to address COVID-19.
“While our most effective extracts require further large-scale validation, our study is crucial for the future analysis of the effects of medical cannabis on COVID-19,” the research said.
“Given the current dire and rapidly evolving epidemiological situation, every possible therapeutic opportunity and avenue must be considered.”